Greg Kennelty

Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.

Nab-paclitaxel provides more benefits than paclitaxel for certain subsets of patients with breast cancer.

An investigation of the tyrosine kinase inhibitor lapatinib plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer.

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

The PD-L1 inhibitor atezolizumab has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

Several variables are important to consider when undergoing preventive surgery for ovarian cancer, including familial history and age.

Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.

Volker Heinemann, MD, PhD, discusses the connection between early tumor shrinkage and overall survival, depth of response, and what it could mean for the future of metastatic colorectal cancer treatment.

Eileen O'Reilly, MD, discusses optimal sequencing of therapies for patients with pancreatic cancer, what potential immunotherapy has in the field, and whether the microenvironments and immune privilege within the malignancy should be understood.

Axel Grothey, MD, discusses both the LUME-1 and LUME-2 trials, the differences between left and right tumors in colorectal cancer, and how that information could potentially be used in diagnosis and treatment.

David Ilson, MD, PhD, discusses pre-operative chemotherapy alone versus chemotherapy plus radiation therapy in patients with esophageal and gastroesophageal-junction cancers, and how data points to the latter being the better choice.

Robert Coleman, MD, and Leslie Randall, MD, provide further insight on the importance of BRCA testing.

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Allison W. Kurian, MD, MSc, discusses 2 clinical trials utilizing multigene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.

Joanne L. Blum, MD, PhD, discusses the design and phase III results from the ABC trials, and what impact the encouraging findings could have in patients with HER2-negative breast cancer.

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

Jennifer Brown, MD, discusses the findings and impact of the RESONATE and RESONATE-2 trials, as well as the role of ibrutinib in older and younger patients with chronic lymphocytic leukemia in both the frontline and relapsed settings.

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

Yong-Chen William Lu, PhD, discusses a phase I dose-escalation study investigating the genetically engineered CD4 T cells' ability to target the MAGE-A3 protein.

Kevin Hughes, MD, discusses the pros and cons of radiation therapy in elderly patients with breast cancer, as well as luminal A patients, and the overall changing role of the treatment in the field.

Oliver Sartor, MD, discusses current research with biomarkers in prostate cancer, as well as how some treatments may be utilized as both single agents and in combination.

Herbert Lepor, MD, discusses the advent of the MRI-US fusion targeted biopsy and what impact it could have on the field of assessing prostate cancer risk.

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Antoni Ribas, MD, PhD, shares exciting clinical trial results of immunotherapy agents in patients with melanoma, as well as what the future holds for the field.

Deficiency in the protein NOD-like receptor X1 (NLRX1) could represent a potential biomarker to predict response to therapies in patients with colorectal cancer.

Edward Kim, MD, discusses the impact of nivolumab (Opdivo) and pembrolizumab (Keytruda) in non–small cell lung cancer, potential combinations, biomarkers, and ongoing research.

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.